Lilly to buy Calytrix Bio for up to $1.5 billion

By Reuters News

- Eli Lilly LLY.N has agreed to acquire Calytrix Bio for up to $1.5 billion in cash to expand the development of treatments for rare blood cancers, the privately held biotech said on Monday.

The move is the latest in a string of acquisitions by the Indianapolis-based pharmaceutical giant as it works to diversify beyond its blockbuster diabetes and weight-loss franchise, the company's primary growth engine.

https://www.reuters.com/graphics/LILLY-DEALS/LILLY-DEALS/byprnyrzdpe/chart.png

The Calytrix transaction includes an upfront payment and additional payments tied to clinical trial and regulatory milestones. Calytrix did not disclose the size of the upfront payment or the deal's expected closing date.

Calytrix's lead candidate is an early-stage antibody treatment for essential thrombocythemia and myelofibrosis – rare blood disorders that cause the bone marrow to produce excessive abnormal blood cells.

The deal is expected to strengthen Lilly's footprint in hematology, adding an experimental treatment to a business that already includes the FDA-approved blood cancer medicine Jaypirca.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.